ArticleOncology letters2020
Comprehensive circular RNA profiling reveals the regulatory role of circ_100242/miR-145 pathway in bladder cancer.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Nanorobots and Exosomes: Driving the New Frontier for Bladder Tumors through Non-Coding RNAs.Oncology research · 2026Review
- MicroRNA-145 in urologic tumors: biological roles, regulatory networks, and clinical translation.Frontiers in pharmacology · 2025Review
- CircOMA1 promotes tumour growth and metastasis of bladder cancer by modulating IGF-IR/MAPK/EMT pathway.Clinical and translational medicine · 2022Article
- Identifying circRNA-miRNA interaction based on multi-biological interaction fusion.Frontiers in microbiology · 2022Article
- Circular RNA Protein Tyrosine Kinase 2 Promotes Cell Proliferation, Migration and Suppresses ApoptosisFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a common genitourinary carcinoma with high morbidity and mortality rates. Circular RNAs (circRNAs), which are a type of single-stranded RNAs, have been characterized as stable, conserved and tissue-specific molecules in mammalian cells. The present study explored the circRNA expression profile in four bladder cancer tissues and matched normal samples by using microarray analysis. Furthermore, bioinformatics analyses were performed to investigate the potential function of dysregulated circRNAs in bladder cancer. The results demonstrated that 89 circRNAs were downregulated and 210 circRNAs were upregulated in bladder cancer tissues. The results from RT-qPCR demonstrated that hsa_circ_100241, hsa_circ_100242 and hsa_circ_101303 were markedly upregulated whereas hsa_circ_104510 was significantly downregulated in bladder cancer tissues compared with normal tissue. Following circRNA/microRNA (miRNA) interaction network generation via Cytoscape, it was demonstrated that hsa_circ_100242 contained a miRNA response element for miR-145-5p, which is a tumor suppressor in bladder carcinoma. In addition, results from the Kyoto Encyclopedia of Genes and Genomes analysis showed that the MAPK signaling pathway was the most significant pathway of the differentially expressed circRNAs in bladder cancer tissues. In conclusion, the present study demonstrated that circRNAs were dysregulated in bladder cancer tissues compared with matched normal samples. Pathway analysis was also performed to predict the binding of miRNAs to the dysregulated circRNAs. The results revealed that hsa_circ_100242 may be involved in bladder cancer initiation and progression by sponging miR-145. These findings may provide further insights into the functional and therapeutic roles of circRNAs in bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.